Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acne Infection01:27

Acne Infection

Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Allergic Contact Dermatitis Caused by Online-Purchased Black Henna Temporary Tattoos.

The Australasian journal of dermatology·2026
Same author

Dupilumab-induced generalized pustular psoriasis in an elderly patient: a case report and literature review.

Anais brasileiros de dermatologia·2026
Same author

Paediatric Psoriasis and the Topical Treatment Guidance Gap in Australia.

The Australasian journal of dermatology·2026
Same author

A rare case of acute generalized exanthematous pustulosis-like Sweet syndrome.

Skin health and disease·2026
Same author

Yellow papules in a young patient.

Clinical and experimental dermatology·2026
Same author

Painful nodules on the feet.

JAAD case reports·2026

Related Experiment Video

Updated: Jul 12, 2026

A Rat Model of Compound Acne
03:10

A Rat Model of Compound Acne

Published on: November 1, 2024

Acneiform Eruption with Deucravacitinib: Systematic Review and Meta-Analysis.

James Gaston1, Andrew Maxwell2, Hieu Chi Ha3

  • 1The Royal Children's Hospital Melbourne, Melbourne, Victoria, Australia.

Clinical and Experimental Dermatology
|July 9, 2026
PubMed
Summary

Acneiform eruptions are a common side effect of deucravacitinib, occurring significantly more often than with placebo. This adverse event rarely leads to treatment discontinuation.

Related Experiment Videos

Last Updated: Jul 12, 2026

A Rat Model of Compound Acne
03:10

A Rat Model of Compound Acne

Published on: November 1, 2024

Area of Science:

  • Dermatology
  • Pharmacology
  • Immunology

Background:

  • Deucravanitib is an oral selective tyrosine kinase 2 (TYK2) inhibitor used for chronic plaque psoriasis.
  • Its application is expanding to other autoinflammatory conditions.
  • Increased reporting of acneiform eruptions associated with deucravanitib use.

Purpose of the Study:

  • Quantify the incidence of acneiform eruptions with deucravanitib.
  • Compare the odds of these events versus placebo.
  • Conduct exploratory analyses by deucravanitib dose and indication.

Main Methods:

  • Systematic literature search of Medline, Embase, and CENTRAL for interventional and observational studies.
  • Random-effects meta-analysis to pool proportions and odds ratios (OR).
  • Primary outcome: incidence of acneiform eruption (acne, folliculitis, dermatitis acneiforme, rosacea).

Main Results:

  • 14 studies included, with 8 controlled studies analyzed.
  • Overall incidence of acneiform eruptions was 8.8% (467/5,280).
  • Pooled incidence in controlled studies: 5.71% for deucravanitib vs. 0.84% for placebo (OR 4.56).
  • Higher odds observed with greater daily doses and in psoriasis/inflammatory bowel disease indications.
  • Discontinuations due to acneiform events were rare (0.21%).

Conclusions:

  • Acneiform eruptions are a frequent cutaneous adverse event associated with deucravanitib.
  • The incidence is significantly higher compared to placebo.
  • Despite frequency, these events seldom necessitate treatment discontinuation.